Read publication

This edition covers the main developments for the period of November 2016, which was a very intense month in terms of developments in both healthcare  legislation and law-enforcement practice. In particular, the long-awaited and extensively-discussed introduction of reference pricing and reimbursement of pharmaceuticals' cost, and the procedure on selection of essential medicines were adopted. In addition, the Antimonopoly Committee of Ukraine has published the report based on the investigation of Ukraine’s pharmaceutical market. More details on the mentioned developments and other legislative novelties are presented below.

In this issue:

  • Pricing and reimbursement
  • Reference pricing and reimbursement
  • Selection of essential medicines
  • Approved register of wholesale prices for insulin preparations
  • Fines for violation of Ukraine’s pricing legislation
  • State control over business activities
  • Law on moratorium on inspections in 2017
  • Antitrust investigation of Ukraine’s pharmaceutical market
  • The AMCU report summarizing the results of the investigation into the pharmaceutical market
  • Government strategy in healthcare
  • Draft National Drug Policy
  • Clinical trials
  • Draft law on publication of pre-clinical and clinical data
  • Other fundamental changes in healthcare and pharmaceutical industry regulation
Explore More Insight
View All